BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that it welcomes the Centers for Medicare & Medicaid Services' (CMS') Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for calendar year 2025 for improved payment for specialized diagnostic radiopharmaceuticals to suppor ...

Investors are cheering a proposed rule that could boost Lantheus' revenue. In the past, CMS has bundled the costs of diagnostic radiopharmaceuticals in with the payment for related nuclear medicine tests. The agency said that in some cases, this payment doesn't fully cover the cost of the associated diagnostic radiopharmaceuticals. CMS is proposing to pay for diagnostic radiopharmaceuticals with a cost greater than $630 per day separately from the nuclear medicine tests. Roughly 70% of Lantheus' total reven ...

BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer. "I'm thrilled to join this purpose-driven organization and to elevate its already-strong culture focused on delivering better patient outcomes," said Ms. Spaeth. " ...

"I'm thrilled to join this purpose-driven organization and to elevate its already-strong culture focused on delivering better patient outcomes," said Ms. Spaeth. "I look forward to working closely with the Executive Team and everyone at Lantheus to engage, attract and develop the talent we need to advance the Company's strategy as the leading radiopharmaceutical-focused company." BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceu ...

BEDFORD, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acquisition of the global rights of Life Molecular Imaging's ("Life Molecular") RM2, targeting the gastrin-releasing peptide receptor (GRPR), including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair, referr ...

"While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate," said Brian Markison, Lantheus CEO. "Targeting GRPR with 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 creates a potential new option to expand access to radiotheranostics for more prostate cancer patients. This expands our therapeutic offerings and opens avenues for commercial synergies." Wolf, Greenfield & Sacks, P.C. acted as legal advisor to Lanth ...

Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024 Option for Lantheus to invest a further A$7.5m within 6 months on the same terms Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement Subject to shareholder approval for the purposes of ASX Listing R ...

Lantheus' leadership in the radiopharmaceuticals market, with PYLARIFY dominating PSMA PET imaging for prostate cancer, looks promising. The company is expanding its pipeline with promising assets like PNT2002, PNT2003, and MK-6240, along with strategic collaborations to enhance its portfolio, including in oncology. Revenues in the Radiopharmaceutical Oncology segment were up 32.1% year over year. The segment's performance reflected solid PYLARIFY sales, driven by increasing utilization of PSMA PET with PYL ...

The latest trading session saw Lantheus Holdings (LNTH) ending at $79.28, denoting a -0.78% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.26% for the day. Meanwhile, the Dow gained 0.18%, and the Nasdaq, a tech-heavy index, added 0.35%. The upcoming earnings release of Lantheus Holdings will be of great interest to investors. In that report, analysts expect Lantheus Holdings to post earnings of $1.83 per share. This would mark year-over-year growth o ...

BEDFORD, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that aPROMISE, its AI-enabled FDAcleared medical device software, is now available on the syngo.via platform, from Siemens Healthineers, one of the leading workstation systems. Siemens Healthineers will be demonstrating the integrated solutio ...